Zacks Research Has Positive Estimate for TBPH Q1 Earnings

Key Points

• Zacks Research raised its Q1 2026 EPS estimate for Theravance Biopharma to $0.01 (from ($0.15)) and rates the stock Strong-Buy, forecasting FY2026 EPS of $0.80.
• Analyst opinions are mixed—two Strong Buy, two Buy and four Hold—resulting in a MarketBeat consensus of Moderate Buy with an average target price of $21.83.
• Shares trade near $16.50 with a market cap of $849.6M and a P/E of 8.13; a senior VP recently sold 31,067 shares and institutional investors own approximately 99.10% of the stock.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Research analysts at Zacks Research upped their Q1 2026 EPS estimates for shares of Theravance Biopharma in a research note issued to investors on Thursday, April 9th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $0.01 per share for the quarter, up from their previous estimate of ($0.15). Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma's Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.62 EPS, FY2026 earnings at $0.80 EPS, Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at $0.43 EPS and FY2027 earnings at $0.28 EPS.

Other research analysts have also issued reports about the stock. Weiss Ratings lowered shares of Theravance Biopharma from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday. BTIG Research reissued a "buy" rating and set a $21.00 target price on shares of Theravance Biopharma in a research note on Friday, March 20th. TD Cowen increased their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a "hold" rating in a research note on Monday, March 23rd. B. Riley Financial raised their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the company a "neutral" rating in a research note on Tuesday, April 7th. Finally, Oppenheimer lowered shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating in a research note on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $21.83.

Theravance Biopharma Stock Up 0.9%

Shares of NASDAQ TBPH opened at $16.50 on Tuesday. The firm has a market cap of $849.63 million, a PE ratio of 8.13 and a beta of 0.17. Theravance Biopharma has a 12-month low of $8.31 and a 12-month high of $21.03. The company's fifty day simple moving average is $16.69 and its 200 day simple moving average is $17.09.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the firm's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president directly owned 232,699 shares of the company's stock, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TBPH. AQR Capital Management LLC bought a new position in shares of Theravance Biopharma during the first quarter valued at about $101,000. Jane Street Group LLC lifted its position in shares of Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after purchasing an additional 88,540 shares in the last quarter. Creative Planning bought a new position in shares of Theravance Biopharma during the second quarter valued at about $139,000. American Century Companies Inc. lifted its position in shares of Theravance Biopharma by 6.8% during the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company's stock valued at $1,009,000 after purchasing an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Theravance Biopharma by 12.4% during the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company's stock valued at $279,000 after purchasing an additional 2,789 shares in the last quarter. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.